This page has not yet been reviewed by a credentialed medical professional. It is educational and is not medical advice.
Why this evidence grade
Animal studies only
Hundreds of rodent studies, mostly from one research group. Human data amounts to three small pilot reports (knee pain, interstitial cystitis and a two-person IV safety pilot).
What it is
BPC-157 is a synthetic 15-amino-acid peptide (GEPPPGKPADDAGLV) derived from a protein found in human gastric juice. It is not a dietary supplement and has never been approved as a drug anywhere. It is sold online as an injectable or oral "research chemical" and is widely promoted on social media for injuries.
How it is thought to work
Proposed mechanisms in animal and cell work include upregulating growth hormone receptor expression in tendon fibroblasts, promoting new blood vessel growth, and modulating nitric oxide signalling. These mechanisms come mainly from lab and rodent experiments and have not been confirmed in controlled human studies. The same 2025 systematic review reports a half-life of under 30 minutes.
What the studies found10 studies explained
A 2025 systematic review of the musculoskeletal literature found 36 eligible studies: 35 preclinical and 1 clinical. Animal studies report faster healing of transected tendons, ligaments, muscle and bone. A 2025 scoping review counts three small human pilot reports: a retrospective chart review of knee injections (17 patients, no control group), a study in interstitial cystitis, and a two-patient IV safety pilot. The peptide was also entered into clinical trials for inflammatory bowel disease under the code PL 14736, but has never been approved.
36 studies (35 preclinical, 1 clinical), 1993 to 2024
What they found
Animal studies consistently report improved healing of muscle, tendon, ligament and bone, with signs of increased growth-hormone receptor expression and reduced inflammatory signalling. No clinical safety data were found.
Limitations
Almost all included studies are animal work, and the review found only level IV and V (lowest quality) evidence. Many animal studies come from the same laboratory group.
Lee E, Padgett B · Altern Ther Health Med · 2021 · PMID 34324435
humanRetrospective chart review with phone survey
Who / how many
17 patients, 16 followed up
What they found
After intra-articular injections of BPC-157 alone or with thymosin beta-4, 14 of 16 patients reported relief of knee pain.
Limitations
No control group, no blinding, self-reported pain by phone months later, no objective function or imaging outcomes, and a variety of knee conditions mixed together. A later systematic review counted a more conservative 7 of 12 with relief beyond six months.
Rats with implanted sponges, diabetic (db/db) mice with skin wounds, and Caco-2 cells
What they found
PL 14736 (BPC-157) stimulated granulation tissue about as selectively as the approved growth factor PDGF-BB, and was more active in promoting early collagen organization. It also switched on the early-response gene egr-1 in cells faster than PDGF-BB.
Limitations
Rodent and cell work only, with European authors including the Zagreb group that has produced much of the BPC-157 literature. Mechanism evidence is in a gut-derived cell line. Not tested in people.
Sikiric P, Seiwerth S, Rucman R · Curr Pharm Des · 2014 · PMID 23755725
reviewNarrative review
Who / how many
BPC-157 and the nitric oxide system across animal injury models
What they found
Argues that BPC-157 interacts with the nitric oxide system and consistently advances healing across many rat injury models, with a very high apparent safety margin in animals (no lethal dose reached).
Limitations
Written by the research group that discovered and mainly studies BPC-157, so it summarizes their own findings. The safety claim comes from animal studies and says nothing about human safety.
McGuire FP, Martinez R, Lenz A · Curr Rev Musculoskelet Med · 2025 · PMID 40789979
reviewScoping review
Who / how many
Preclinical and clinical BPC-157 literature on musculoskeletal healing
What they found
Reports that BPC-157 acts through several overlapping pathways in animals (VEGFR2, nitric oxide synthesis via Akt-eNOS, ERK1/2) and has broad preclinical support. Only three pilot studies exist in humans (knee pain, interstitial cystitis, and IV safety). The authors conclude it should be considered investigational until proper clinical trials are done.
Limitations
A scoping review summarizes what exists and does not grade quality or pool results. The mechanisms are drawn from animal and cell work.
Chang CH, Tsai WC, Lin MS · J Appl Physiol (1985) · 2011 · PMID 21030672
cellsCell culture experiment
Who / how many
Rat Achilles tendon explants and tendon fibroblasts
What they found
BPC-157 sped up outgrowth of fibroblasts from tendon tissue, improved cell survival under oxidative stress, and increased cell migration and spreading, apparently by activating the FAK-paxillin pathway. It did not directly increase cell proliferation.
Limitations
Test-tube study using rat cells. It suggests a mechanism but does not show tendons heal faster in a living person.
Cerovecki T, Bojanic I, Brcic L · J Orthop Res · 2010 · PMID 20225319
animalControlled animal experiment
Who / how many
Rats with surgically cut medial collateral ligaments, followed 90 days
What they found
BPC-157 given by injection, in drinking water, or as a topical cream improved functional, biomechanical, macroscopic and microscopic ligament healing compared with controls.
Limitations
Rat model from the group that discovered the peptide. Oral and topical dosing were tested only in rats, and the results have not been replicated in people.
Approved and unapproved peptides used in sports medicine (BPC-157, TB-500, CJC-1295, ipamorelin, GHK-Cu and others)
What they found
Many unapproved peptides show tissue-repair or metabolic benefits in animals, but rigorous human safety data are scarce and there is potential for serious harm. The authors also discuss the placebo effect and how social media amplifies it.
Limitations
A narrative review rather than a systematic one. It frames how clinicians should talk to patients rather than testing efficacy.
2 trials on ClinicalTrials.gov list BPC-157 as an intervention; the most advanced are shown. Registration is not evidence of benefit: many trials are ongoing, unpublished or never reported results.
Data pulled from the ClinicalTrials.gov API. Check sponsors: several newer peptide registrations come from companies that also sell the product.
European research
221 records in Europe PMC mention BPC-157 in the title or abstract. Of the 25 most-cited with European author affiliations that we sampled, the most common countries were Croatia (25).
No serious adverse events have been reported in the few human reports, but those reports cover under 20 people in total and cannot rule out risk. Reviewers note there are no real clinical safety data in humans. Real-world risk also comes from unregulated manufacturing: contamination, wrong dose, and wrong compound. Because BPC-157 promotes blood vessel growth in lab models, some researchers have raised a theoretical concern in people with cancer; this is unproven either way.
Legal status
United States
Not FDA-approved. Status for pharmacy compounding is actively changing: FDA moved it off its "Category 2" (significant safety risk) list in April 2026 and an FDA advisory committee narrowly voted in July 2026 in favour of easing restrictions, but no final FDA decision had been confirmed in the sources checked.
Canada
Not authorized by Health Canada. Named in a Health Canada public advisory as an unauthorized injectable peptide; "research use only" labels do not make sale for human use legal.
European Union
No EU marketing authorization from the European Medicines Agency (EMA). Not a lawful medicine or supplement in the EU; national rules on compounding and enforcement vary by country.
Sport (WADA)
Prohibited at all times in sport (S0: non-approved substances).
Nobody can say yet. Rodent studies show no obvious organ toxicity, but a 2025 systematic review found no clinical safety data in humans. The only human safety report covers two people over three days.
Are there human studies on BPC-157?
Very few. A 2025 scoping review found three small pilot reports: a 2021 retrospective review of 17 patients who received knee injections, a study in interstitial cystitis, and a 2025 pilot in which 2 people received IV infusions. None was a randomized controlled trial.
Is BPC-157 legal?
It is not an approved drug in the US or Canada. US compounding rules were changing during 2026; check the legal tracker for the latest verified date. It is prohibited in sport by WADA.
